"Deferoxamine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
| Descriptor ID |
D003676
|
| MeSH Number(s) |
D02.092.570.394.265 D02.241.511.372.265
|
| Concept/Terms |
Deferoxamine- Deferoxamine
- Desferrioxamine
- Desferioximine
- Deferoxamine B
- Desferrioxamine B
- Deferoximine
- Deferrioxamine B
- Desferroxamine
Desferrioxamine B Mesylate- Desferrioxamine B Mesylate
- Mesylate, Desferrioxamine B
- Deferoxamine Mesilate
- Mesilate, Deferoxamine
- Deferoxamine Mesylate
- Mesylate, Deferoxamine
- Deferoxamine Methanesulfonate
- Methanesulfonate, Deferoxamine
|
Below are MeSH descriptors whose meaning is more general than "Deferoxamine".
Below are MeSH descriptors whose meaning is more specific than "Deferoxamine".
This graph shows the total number of publications written about "Deferoxamine" by people in this website by year, and whether "Deferoxamine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 1 | 1 |
| 2002 | 1 | 0 | 1 |
| 2008 | 1 | 0 | 1 |
| 2009 | 0 | 1 | 1 |
| 2013 | 0 | 1 | 1 |
| 2015 | 1 | 0 | 1 |
| 2018 | 1 | 2 | 3 |
| 2020 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Deferoxamine" by people in Profiles.
-
Peng D, Chen CA, Ruhela D, Li Y, Regan RF. Deferoxamine deconditioning increases neuronal vulnerability to hemoglobin. Exp Cell Res. 2020 05 01; 390(1):111926.
-
Agrawal M, Saraf S, Saraf S, Antimisiaris SG, Chougule MB, Shoyele SA, Alexander A. Nose-to-brain drug delivery: An update on clinical challenges and progress towards approval of anti-Alzheimer drugs. J Control Release. 2018 07 10; 281:139-177.
-
Lee JA, Tchantchaleishvili V, Vidula H. Cardiac Hemochromatosis Treated With Prolonged Extracorporeal Membrane Oxygenation Support and Chelation Therapy. Artif Organs. 2018 May; 42(5):575-576.
-
Chen-Roetling J, Ma SK, Cao Y, Shah A, Regan RF. Hemopexin increases the neurotoxicity of hemoglobin when haptoglobin is absent. J Neurochem. 2018 06; 145(6):464-473.
-
Rassu G, Soddu E, Cossu M, Brundu A, Cerri G, Marchetti N, Ferraro L, Regan RF, Giunchedi P, Gavini E, Dalpiaz A. Solid microparticles based on chitosan or methyl-?-cyclodextrin: a first formulative approach to increase the nose-to-brain transport of deferoxamine mesylate. J Control Release. 2015 Mar 10; 201:68-77.
-
Chen-Roetling J, Cai Y, Lu X, Regan RF. Hemin uptake and release by neurons and glia. Free Radic Res. 2014 Feb; 48(2):200-5.
-
Chen-Roetling J, Chen L, Regan RF. Minocycline attenuates iron neurotoxicity in cortical cell cultures. Biochem Biophys Res Commun. 2009 Aug 21; 386(2):322-6.
-
Potier E, Ferreira E, Dennler S, Mauviel A, Oudina K, Logeart-Avramoglou D, Petite H. Desferrioxamine-driven upregulation of angiogenic factor expression by human bone marrow stromal cells. J Tissue Eng Regen Med. 2008 Jul; 2(5):272-8.
-
Karimi M, Asadi-Pooya AA, Khademi B, Asadi-Pooya K, Yarmohammadi H. Evaluation of the incidence of sensorineural hearing loss in beta-thalassemia major patients under regular chelation therapy with desferrioxamine. Acta Haematol. 2002; 108(2):79-83.
-
Zhang W, Johnson BR, Bjornsson TD. Pharmacologic inhibition of transglutaminase-induced cross-linking of Alzheimer's amyloid beta-peptide. Life Sci. 1997; 60(25):2323-32.